For MAPK-related cancers, biomarkers in the intermediate layer (RAS/RAF/MEK or P38) have proven to be most efficacious, as opposed to the biomarkers in the cell surface receptor (input) or downstream (output) layers.51 This evidence concerns the gene CD177 and cancer.